Reply
Jerzy W. Kupiec‐Weglinski, Naoko Kamo – 20 May 2013
Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome
Joseph E. Khabbaza, Richard A. Krasuski, Adriano R. Tonelli – 20 May 2013
Lipocalin‐2 negatively modulates the epithelial‐to‐mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF‐beta1)/Lcn2/Twist1 pathway
Yun‐Peng Wang, Goung‐Ran Yu, Mi‐Jin Lee, Sang‐Yeop Lee, In‐Sun Chu, Sun‐Hee Leem, Dae‐Ghon Kim – 20 May 2013 – Lipocalin‐2 (Lcn2) is preferentially expressed in hepatocellular carcinoma (HCC). However, the functional role of Lcn2 in HCC progression is still poorly understood, particularly with respect to its involvement in invasion and metastasis. The purpose of this study was to investigate whether Lcn2 is associated with the epithelial‐mesenchymal transition (EMT) in HCC and to elucidate the underlying signaling pathway(s).
Cognitive improvement after HCV eradication: Extending the benefits
Jasmohan S. Bajaj, Daniel M. Forton – 20 May 2013
Does mild resistance training resemble a similar stimulus compared to aerobic training?
Dominik Pesta, Martin Burtscher – 20 May 2013
Platelet‐derived growth factor D: A new player in the complex cross‐talk between cholangiocarcinoma cells and cancer‐associated fibroblasts
Carmen Berasain, Matias A. Ávila – 20 May 2013
Hepatocellular cancer risk in diabetes: Not all diabetics are the same
Siddharth Singh, Preet Paul Singh – 20 May 2013
Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis
Aaron Turkish, Jean J. Luo, Jay H. Lefkowitch – 20 May 2013
Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome
Joseph E. Khabbaza, Richard A. Krasuski, Adriano R. Tonelli – 20 May 2013
Donor risk index for African American liver transplant recipients with hepatitis C virus
Nathan J. Shores, Jennifer L. Dodge, Sandy Feng, Norah A. Terrault – 20 May 2013 – African American (AA) liver transplant (LT) recipients with hepatitis C virus (HCV) have higher rates of graft loss than other racial/ethnic groups. The Donor Risk Index (DRI) predicts graft loss but is neither race‐ nor disease‐specific and may not be optimal for assessing donor risk for AA HCV‐positive LT recipients. We developed a DRI for AA with HCV with the goal of enhancing graft loss predictions. All U.S.